Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Mol Cancer Res. 2018 Nov 16;17(2):604–617. doi: 10.1158/1541-7786.MCR-18-0750

Figure 2. Knockout of stromal CCL2 inhibits growth of primary MCF10CA1d breast tumor xenografts.

Figure 2.

A. CCL2 ELISA of conditioned medium from Parental (Par), control wildtype (WT) or CCL2 knockout (CCL2KO#7, CCL2KO#22) hCAF-1 cell lines. B-C. MCF10CA1d breast cancer cells were co-grafted with WT or CCL2KO fibroblasts for up to 6 weeks and measured for changes in tumor volume over time (B) or endpoint tumor mass (C). D-G. Breast tumor xenografts were immunostained for GFP (D), arginase I (E), Ly6G (F), or Von Willebrand Factor 8 (VWF8) (G). -GFP control is MCF10CA1d co-grafted with hCAF-1 parental fibroblasts.. Expression was quantified by Image J. Statistical analysis was performed using One Way ANOVA with Bonferroni post-hoc comparison. Statistical significance was determined by p<0.05. *p<0.05, ***p<0.001., n.s = not significant. Mean±SEM are shown.